Low demand is prompting drugmaker Roche to discontinue two of its anti-HIV drugs, AIDSmap.com reports. The company will stop production of its nucleoside reverse transcriptase inhibitor Hivid, also known as ddC, and its protease inhibitor Fortovase. Hivid is rarely prescribed by physicians because studies have shown it can cause peripheral neuropathy in as many as 31% of the HIV patients taking it. Roche's protease inhibitor Fortovase is not as well-tolerated as its other protease drug, Invirase, say company officials. The drugs will be discontinued in 2006 or shortly thereafter.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved















